SAN FRANCISCO: ORAL THRUSH STUDY

Persons with oral thrush are needed to help test a new anti-fungal at San Francisco General Hospital. The study, conducted by Merle Sande, M. D., and others at the Department of Medicine, lasts only 10 days.

The drug, from Schering Corp., is known as SCH 39304. Patients will randomly be assigned to one of three groups: ketoconazole 200 mg daily, SCH 39304 25 mg daily, or SCH 39304 50 mg daily. Blood samples will be drawn on da requiring a visit to the clinic on those days.

Although the drug does not yet have a name, this is a phase III study; SCH 39304 has already been given to dozens of people, and only occasional minor side effects have occurred.

To volunteer or to learn more about this study, call Dr. Belle Lee, Pharm. D., at 415/821-8450.